Cite
HARVARD Citation
Brandt, C. et al. (2018). Corrigendum to "Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's antiseizure efficacy" [Neuropharmacology 143 (2018) 186–204]. Neuropharmacology. pp. 349-350. [Online].